• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Opko Health Inc. acquires rights for dry eye treatment

Article

Miami-Exclusive rights were acquired by Opko Health Inc. to develop a topical formulation of civamide for ophthalmic use, such as the treatment of dry eye.

Miami-Exclusive rights were acquired by Opko Health Inc. to develop a topical formulation of civamide for ophthalmic use, such as the treatment of dry eye.

Increased tear production was found in more than 50% of treated patients and there were no systematic side effects.

Currently there is only one prescription product approved by FDA for the treatment of dry eye disease.

No terms of the agreement or the company that sold the rights were stated. An intranasal formulation of civamide channel blocker, is being reviewed in phase III trials as a possible treatment for pain.

Related Videos
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
© 2024 MJH Life Sciences

All rights reserved.